Home › Research › Drug development
Current and evolving treatment strategies for the Alzheimer disease continuum
Marasco RA.. The American journal of managed care, 2020-08-01
Topic: Amyloid, tau and blood-test diagnosis
The burden of Alzheimer disease (AD) on the US healthcare system is substantial and increasing. AD progresses along a continuum from preclinical disease characterized by normal cognition and abnormal brain biomarkers to mild cognitive impairment and then clinically apparent dementia. Diagnosis early in the AD continuum has benefits for patients and caregivers and appears cost-effective, but often, the clinical diagnosis of AD may be delayed.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Marasco, R. A. (2020). Current and evolving treatment strategies for the Alzheimer disease continuum. The American journal of managed care. https://doi.org/10.37765/ajmc.2020.88481
Vancouver
Marasco RA. Current and evolving treatment strategies for the Alzheimer disease continuum. The American journal of managed care. 2020. doi:10.37765/ajmc.2020.88481. PMID: 32840330.
BibTeX
@article{marasco2020-32840330,
author = {Marasco, R. A.},
title = {{Current and evolving treatment strategies for the Alzheimer disease continuum}},
journal = {The American journal of managed care},
year = {2020},
doi = {10.37765/ajmc.2020.88481},
pmid = {32840330},
url = {https://doi.org/10.37765/ajmc.2020.88481}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- AD progresses along a continuum from preclinical disease characterized by normal cognition and abnormal brain biomarkers to mild cognitive impairment and then clinically apparent dementia.
- Diagnosis early in the AD continuum has benefits for patients and caregivers and appears cost-effective, but often, the clinical diagnosis of AD may be delayed.
- Currently available biomarkers include β-amyloid positron emission tomography and cerebrospinal fluid tests.
- Collectively, they are expensive, may lead to adverse effects, are not widely available, and are not suited for primary care.
Why it matters
This review describes Alzheimer's disease as progressing along a continuum from preclinical disease to mild cognitive impairment and then dementia, and states that early diagnosis has benefits for patients and caregivers and appears cost-effective. It notes that currently available biomarkers such as amyloid PET and cerebrospinal fluid tests are expensive.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Study designclinical trial
- Evidence strengthLow
How this study scored 39/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomised / blinded because the record does not state it. We have no data on senior author's track record, so that was left out: it earned 37 of the 96 points we could judge it on, which is 39 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (The American journal of managed care) |
| Journal's citation record | 0 / 4 | The American Journal of Managed Care: journal h-index 38 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | Design recorded as “clinical trial”, which our rubric does not rank (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 2 / 5 | 2020 — within 10 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomised / blinded | 0 / 2 | No randomisation or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 4 / 7 | Cited 66 times (OpenAlex, 2026-10-10) |
| Citations per year | 3 / 5 | 8.2 citations a year over 8 year(s) since 2020 |
| Impact for its field and year | 3 / 6 | Cited 4.6× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 2 / 6 | Cited by 8 other studies in this library |
| Still being cited | 2 / 4 | Cited 37 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | 0 / 3 | Mercer University: institution h-index 196 (OpenAlex) |
| Multi-centre collaboration | 1 / 3 | OpenAlex lists 2 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 32840330) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Points | 37 / 96 | Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 37 of the 96 points we could judge it on is 39 out of 100. |
| Total | 39 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it. The PubMed abstract is free.
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 33.
Later studies that cite this one
8 studies in the alzhub library list this one in their references.
Related studies in Drug development
Also in Drug development
95 studies in the library are filed under Drug development with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Drug development hub.